Latest & greatest articles for knee osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on knee osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on knee osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for knee osteoarthritis

121. Walking cane: knee osteoarthritis

Media Releases 2013 Media Releases 2012 Media Releases Search Walking cane for knee osteoarthritis Walking cane for knee osteoarthritis Introduction Use of a cane is one of a number of non-drug treatments for knee osteoarthritis; which include weight reduction, exercise and taping. Intervention Daily use of a walking cane or stick to decrease the load transmitted through the affected knee(s) and improve pain and function. Indication People with knee osteoarthritis (OA) who have pain and difficulty (...) Walking cane: knee osteoarthritis RACGP - Walking cane for knee osteoarthritis Search Become a student member today for free and be part of the RACGP community A career in general practice Starting the GP journey Enrolments for the 2019.1 OSCE FRACGP exams closing 29 March 2019 Fellowship FRACGP exams Research Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP Fellowship Fellowship International

2016 Handbook of Non-Drug interventions (HANDI)

122. Exercise for knee osteoarthritis

Exercise for knee osteoarthritis RACGP - Handbook of Non-Drug Interventions (HANDI) Search Become a student member today for free and be part of the RACGP community A career in general practice Starting the GP journey Enrolments for the 2019.1 OSCE FRACGP exams closing 29 March 2019 Fellowship FRACGP exams Research Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP Fellowship Fellowship International

2016 Handbook of Non-Drug interventions (HANDI)

123. Randomised controlled trial: NSAIDs or paracetamol for short-term treatment of mild to moderate knee pain in early osteoarthritis: are they equivalent?

: are they equivalent? Article Text Therapeutics/Prevention Randomised controlled trial NSAIDs or paracetamol for short-term treatment of mild to moderate knee pain in early osteoarthritis: are they equivalent? Philip G Conaghan Statistics from Altmetric.com Commentary on : Verkleij SP , Luijsterburg PA , Willemsen SP , et al . Effectiveness of diclofenac versus paracetamol in knee osteoarthritis: a randomised controlled trial in primary care . Context Management of osteoarthritis (OA) in primary care is often (...) Randomised controlled trial: NSAIDs or paracetamol for short-term treatment of mild to moderate knee pain in early osteoarthritis: are they equivalent? NSAIDs or paracetamol for short-term treatment of mild to moderate knee pain in early osteoarthritis: are they equivalent? | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies

2016 Evidence-Based Medicine

124. In adult patients immediately post primary total knee replacement (TKR) for osteoarthritis (OA) is group therapy more clinically effective than an individual programme for pain and function?

In adult patients immediately post primary total knee replacement (TKR) for osteoarthritis (OA) is group therapy more clinically effective than an individual programme for pain and function? Musculoskeletal Research Facilitation Group (Cat Group) Critically appraised topic and clinical bottom line Date: April 2016 CAT Lead: Mark Buckley Date CAT completed: April 2016 Email: markbuckley1@nhs.net Date CAT to be reviewed: April 2018 Specific Question: In adult patients immediately post primary (...) total knee replacement (TKR) for osteoarthritis (OA) is group therapy more clinically effective than an individual programme for pain and function? Clinical bottom line After TKR, group rehabilitation is not more effective than individual rehabilitation. Individual rehabilitation appears similarly effective if undertaken as a package of 2 initial individual face-to-face treatment sessions followed by telephone support for a home exercise programme or as a package of 12 individual treatment sessions

2016 Public Health England

125. Efficacy of Triamcinolone Hexacetonide versus Methylprednisolone Acetate Intraarticular Injections in Knee Osteoarthritis: A Randomized, Double-blinded, 24-week Study (Abstract)

Efficacy of Triamcinolone Hexacetonide versus Methylprednisolone Acetate Intraarticular Injections in Knee Osteoarthritis: A Randomized, Double-blinded, 24-week Study Intraarticular (IA) corticosteroid injections are broadly used in knee osteoarthritis (OA); however, the best corticosteroid agent is not well defined. The aim of the present study was to compare the efficacy of triamcinolone hexacetonide (TH) and methylprednisolone acetate (MA) injections in knee OA.Patients with symptomatic knee (...) OA and Kellgren-Lawrence grade II or III were randomized to receive 40 mg of IA TH or MA. Evaluations were performed at 4, 12, and 24 weeks. The primary outcome was a change in the patient's assessment of pain by visual analog scale from baseline to Week 4. Secondary outcomes included a global assessment of the disease by patients and physicians, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequesne index (LI), and Outcome Measures in Rheumatology Clinical Trials

2015 EvidenceUpdates Controlled trial quality: predicted high

126. Joint distraction for knee osteoarthritis without alignment correction

information on the evidence, see the interventional procedure overview. 4.1 A case series of 20 patients with end-stage knee osteoarthritis treated by joint distraction reported significant improvements in Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores (normalised to a 100-point scale for total and subscales; 100 being the best score) of 70% at 1-year follow-up and of 74% at 2-year follow-up (p<0.001 for both improvements from baseline). The individual components of the WOMAC (...) Joint distraction for knee osteoarthritis without alignment correction Joint distr Joint distraction for knee osteoarthritis without action for knee osteoarthritis without alignment correction alignment correction Interventional procedures guidance Published: 23 July 2015 nice.org.uk/guidance/ipg529 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare

2015 National Institute for Health and Clinical Excellence - Interventional Procedures

127. Viscosupplementation for Knee Osteoarthritis

(DC): Department of Veterans Affairs, Department of Defense; 2014. [cited 2015 Apr 17]. Available from: http://www.healthquality.va.gov/guidelines/CD/OA/VADoDOAClinicianSummaryFINAL090 214.pdf See: Recommendation 23, page 5 8. American Academy of Orthopaedic Surgeons clinical practice guideline on treatment of osteoarthritis of the knee [Internet]. 2nd ed. Rosemont (IL): American Academy of Orthopaedic Surgeons (AAOS); 2013 May 18. [cited 2015 Apr 17]. Available from: http://www.aaos.org/research (...) /guidelines/TreatmentofOsteoarthritisoftheKneeGuideline.pdf See: Recommendation 9, page 770 9. Work Loss Data Institute. Knee & leg (acute & chronic). Encinitas (CA): Work Loss Data Institute; 2013 Nov 29. Summary available from: http://www.guideline.gov/content.aspx?id=47585 See: Arthritis, ODG Return-To-Work Pathways Viscosupplementation for Knee Osteoarthritis 4 10. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

128. Effectiveness of a cognitive-behavioural group intervention for knee osteoarthritis pain: A randomized controlled trial (Abstract)

Effectiveness of a cognitive-behavioural group intervention for knee osteoarthritis pain: A randomized controlled trial To assess the effectiveness of a six week cognitive-behavioural group intervention in patients with knee osteoarthritis pain.Single-blinded randomized controlled trial.Primary care providers in a medium-sized city in Finland.A total of 111 participants aged from 35 to 75 with clinical symptoms and radiographic grading (Kellgren-Lawrence 2-4) of knee osteoarthritis were (...) group (Pr = 0.038). Conventional group comparisons of mean follow-up values showed no significant differences in any of the outcome variables.This trial could not confirm the hypothesized advantage of a cognitive-behavioural training programme over ordinary GP care in knee osteoarthritis pain patients.Current Controlled Trials ISRCTN64794760.© The Author(s) 2014.

2015 EvidenceUpdates Controlled trial quality: predicted high

129. Systematic review with meta-analysis: Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis

Systematic review with meta-analysis: Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis Article Text Therapeutics/Prevention Systematic review with meta-analysis Paracetamol is ineffective for spinal pain and knee

2015 Evidence-Based Medicine

130. Systematic review with meta analysis: In knee osteoarthritis, pharmacological interventions, with the exception of acetaminophen, significantly improve pain; with intra-articular administration being more effective

Commentary on: Bannuru RR , Schmid CH , Kent DM , et al . Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis . Context Knee osteoarthritis (OA) is a progressive degenerative disease affecting many individuals worldwide. Owing to high disease burden and increasing healthcare costs, the relative efficacy of different treatment options have been extensively studied. 1 , 2 There have been numerous studies comparing effectiveness (...) Systematic review with meta analysis: In knee osteoarthritis, pharmacological interventions, with the exception of acetaminophen, significantly improve pain; with intra-articular administration being more effective In knee osteoarthritis, pharmacological interventions, with the exception of acetaminophen, significantly improve pain; with intra-articular administration being more effective | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content

2015 Evidence-Based Medicine

131. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial Full Text available with Trip Pro

Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial This trial aimed to test the effectiveness of a wearable pulsed electromagnetic fields (PEMF) device in the management of pain in knee OA patients.In this randomized [with equal randomization (1:1)], double-blind, placebo-controlled clinical trial, patients with radiographic evidence of knee OA and persistent pain higher than 40 mm on the visual analog scale (VAS) were recruited (...) . The trial consisted of 12 h daily treatment for 1 month in 60 knee OA patients. The primary outcome measure was the reduction in pain intensity, assessed through VAS and WOMAC scores. Secondary outcomes included quality of life assessment through the 36-item Medical Outcomes Study Short-Form version 2 (SF-36 v2), pressure pain threshold (PPT) and changes in intake of NSAIDs/analgesics.Sixty-six patients were included, and 60 completed the study. After 1 month, PEMF induced a significant reduction in VAS

2015 EvidenceUpdates Controlled trial quality: predicted high

132. Systematic review for effectiveness of hyaluronic acid in the treatment of severe degenerative joint disease(DJD) of the knee

. 2015 Authors' objectives The Coverage and Analysis Group at the Centers for Medicare and Medicaid Services (CMS) requested from The Technology Assessment Program (TAP) at the Agency for Healthcare Research and Quality (AHRQ), a review of the evidence that intraarticular injections of hyaluronic acid (HA) in individuals with degenerative joint disease (osteoarthritis [HA]) of the knee improve function and quality of life (QoL) and that they delay or prevent the need for total knee replacement (TKR (...) Systematic review for effectiveness of hyaluronic acid in the treatment of severe degenerative joint disease(DJD) of the knee Systematic review for effectiveness of hyaluronic acid in the treatment of severe degenerative joint disease (DJD) of the knee Systematic review for effectiveness of hyaluronic acid in the treatment of severe degenerative joint disease (DJD) of the knee Newberry SJ, Fitzgerald JD, Maglione MA, O'Hanlon CE, Booth M, Motala A, Timmer M, Shanman R, Shekelle PG Record Status

2015 Health Technology Assessment (HTA) Database.

133. Knee Osteoarthritis

Knee Osteoarthritis 1 Osteoarthritis (OA) of the Knee Management Options Brief Decision Aid There are many different options for the management of osteoarthritis. These can be split into four main groups. It is possible to try combinations of some options: ? Lifestyle changes – increasing exercise, weight loss (if overweight). ? Physical treatments – physiotherapy, shoe insoles, knee supports, walking aids, heat, TENS machine. ? Pain medication – tablets, creams/gels or injections (...) reduce the chance of arthritis worsening? Benefits and Risks of Lifestyle changes Treatment option Benefits Risks/ consequences General exercise (aiming for minimum 2.5 hours a week e.g. 5x30mins). Knee exercises (see physiotherapy). Helps strengthen muscles and joints, to keep you fit, and maintain good range of joint movement. Reduces pain in arthritic joints. Can also help you lose weight. Knee exercise can help you walk further and faster. Knee exercises may protect the joint and slow down

2015 SickKids Reports

134. Intra-Articular Hyaluronic Acid for Osteoarthritis of the Knee

and Blue Shield Association Medical Advisory Panel made the following judgments about whether the use of intra-articular hyaluronic acid (IAHA) for knee osteoarthritis (OA) meets the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC) criteria. 1. The technology must have final approval from the appropriate governmental regulatory bodies. Seven different formulations of hyaluronic acid products are currently approved for marketing in the United States for intra-articular injection (...) in the knee. All were approved as class III devices via the U.S. Food and Drug Administration's Premarket Application approval process. All 7 devices are indicated for the "treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy, and simple analgesics, e.g., acetaminophen." 2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes. Although a large body of evidence

2015 Health Technology Assessment (HTA) Database.

135. Dolenio (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

- 36]; - among the 15 patients who provided information on the location of the arthritis, the majority reported the knee as the main joint affected by arthritis (11/15) and also reported at least one other secondary arthritis location; - the median delay between the onset of osteoarthritis reported by the patient and prescription of DOLENIO was 21 months [extremes: 2 - 343]; - the median pain score reported by the patient for the month of inclusion (score from 0 to 10) was 6.5 [extremes: 0 - 9 (...) of symptoms related to mild to moderate osteoarthritis of the knee): DOLENIO, FLEXEA, OSAFLEXAN, STRUCTOFLEX and VOLTAFLEX. Due to their low efficacy on pain and joint function, the Committee believed that the potential benefit of these treatments, in particular glucosamine, would reside in a possible reduction of NSAID consumption. Its favourable opinion for continued listing or inclusion of all delayed-effect symptomatic treatments for osteoarthritis depended on setting up and conducting a study, within

2014 Haute Autorite de sante

136. Flexea (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

deviation: 5.0]; - known diagnoses were knee arthritis (79.4%), hip arthritis (16.4%) both (4.3%); - osteoarthritis present for 5 years (30.3%) - median number of pain flare-ups in the past 6 months (2.0 [range: 0.0 - 12.0]; - mean pain score (measured from 0 to 10 on the VAS) 5.6 [standard deviation: 1.8]; - disability (Lequesne algofunctional index) significant to very significant (35.3%), unbearable (18.8%); - main co-morbidities musculo-skeletal disorders (58.9%), cardiovascular disease (57.2 (...) (NSAID or analgesics, infiltration) or non-pharmacological (lifestyle/dietary measures, physiotherapy, orthotics, other forms of physical therapy) - was started. 1 Altman, R et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039-49. 2 Altman, R et al: The American College of Rheumatology criteria

2014 Haute Autorite de sante

137. Osaflexan (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

, ZONDAR, CHONDROSULF and PIASCLEDINE) and, in 2009-2010, examined the various applications for inclusion of glucosamine-based proprietary medicinal products and other delayed-effect symptomatic treatments with a similar indication (relief of symptoms related to mild to moderate osteoarthritis of the knee): DOLENIO, FLEXEA, OSAFLEXAN, STRUCTOFLEX and VOLTAFLEX. Due to their low efficacy on pain and joint function, the Committee believed that the potential benefit of these treatments, in particular (...) with knee or hip arthritis, treated or not treated by delayed-effect symptomatic osteoarthritis medicines, including glucosamine-based medicines, which aimed to measure their impact on NSAID use and describe their usage profile during follow-up. This study, which began including patients in March 2010, was conducted on a sample of generalist physicians or rheumatologists in private practice in metropolitan France and identified at random from telephone lists. This cohort comprised patients aged 18 years

2014 Haute Autorite de sante

138. Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/8 The legally binding text is the original French version TRANSPARENCY C OMMITTEE Opinion 20 November 2013 VOLTAFLEX 625 mg, film-coated tablet B/60 tablets (CIP: 34009 384 573 2) Applicant: NOVARTIS SANTÉ FAMILIALE S.A.S. INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason (...) for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 10 March 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." HAS - Medical, Economic and Public Health Assessment Division 2/8 Actual Benefit Insufficient Actual Benefit Therapeutic Use Due to the very modest efficacy on pain and functional disability

2014 Haute Autorite de sante

139. Structoflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

symptomatic treatments with a similar indication (relief of symptoms related to mild to moderate osteoarthritis of the knee): DOLENIO, FLEXEA, OSAFLEXAN, STRUCTOFLEX and VOLTAFLEX. Due to their low efficacy on pain and joint function, the Committee believed that the potential benefit of these treatments, in particular glucosamine-based medicines, would reside in a possible reduction of NSAID consumption. Its favourable opinion for continued listing or inclusion of these proprietary medicinal products (...) depended on setting up and conducting a study, within two years after marketing (deadline of 30 June 2013), to show their impact in terms of reducing NSAID consumption. To meet the Transparency Committee's request dated on 13 January 2010, Pierre Fabre Médicaments participated in the PEGASE study. As a reminder, PEGASE is a cohort study of patients with knee or hip arthritis, treated or not treated by delayed-effect symptomatic osteoarthritis medicines including glucosamine-based medicines, which aimed

2014 Haute Autorite de sante

140. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines

Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation CADTH. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Nine systematic reviews and eight evidence-based guidelines were identified regarding viscosupplementation for the treatment of patients with osteoarthritis of the knee. Final publication URL Indexing Status

2014 Health Technology Assessment (HTA) Database.